Previous close | 11.40 |
Open | 11.40 |
Bid | 10.20 |
Ask | 12.40 |
Strike | 20.00 |
Expiry date | 2025-01-17 |
Day's range | 11.40 - 11.40 |
Contract range | N/A |
Volume | |
Open interest | 1 |
Helen Thackray, Chief Research & Development Officer of BioCryst Pharmaceuticals Inc (NASDAQ:BCRX), purchased 30,000 shares of the company on May 14, 2024.
On May 13, 2024, Steven Galson, a Director at BioCryst Pharmaceuticals Inc (NASDAQ:BCRX), purchased 21,940 shares of the company, as reported in a recent SEC Filing.
Charles Gayer, Chief Commercial Officer of BioCryst Pharmaceuticals Inc (NASDAQ:BCRX), purchased 30,000 shares of the company on May 13, 2024.